Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reata Pharmaceuticals Inc.

www.reatapharma.com

Latest From Reata Pharmaceuticals Inc.

Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe

Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone – which the company is buying back from AbbVie for $330m.
Rare Diseases Clinical Trials

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Deals Business Strategies

Reata Expands Options For Bardoxolone With New CKD Data

Once suspended due to safety issues, bardoxolone now has completed a Phase II study that showed kidney function benefit in four rare types of CKD. A pivotal study is underway, with another planned and more possible.

Clinical Trials Research & Development

Pay Day For Reata As Bardoxolone Progresses For Kidney Disease In Japan

Reata reaps benefit from 2009 licensing deal with Kyowa Hakko Kirin for bardoxolone as transcription factor activator moves into pivotal study for kidney disease in Japan.

Japan Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Reata Discovery Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Reata Pharmaceuticals Inc.
  • Senior Management
  • Warren Huff, Pres. & CEO
    Manmeet S Soni, EVP, CFO
    Colin Meyer, MD, EVP, Product Dev. & CMO
    Joel Proksch, PhD, Chief Development Officer
    Dawn C Bir, VP, Chief Commercial Officer
  • Contact Info
  • Reata Pharmaceuticals Inc.
    Phone: (972) 865-2219
    2801 Gateway Dr., Ste. 150
    Irving, TX 75063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register